An observational study in Endometrial Cancer, Vulvar Cancers and Cervical Cancer, sponsored by Cukurova University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Cukurova University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Endometrial Neoplasms with a site in Turkey — 14 open to participants now, 18 under way, 4 of them phase 3. Endometrial Neoplasms · Turkey.
Among the 46 studies in Endometrial Neoplasms with a site in Turkey, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 7 that started in 2025, is one of 13 observational ones, reaches primary completion later than 6 of the 17 other live ones, and was the 42nd registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →14 of the 46 studies in Endometrial Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Mahmut Yassa · Sites in Turkey
Ages 18–90 · Women only
BioNTech SE · Sites in Turkey, United States, Argentina and 24 more countries
Ages 18+ · Women only
Dokuz Eylul University · Sites in Turkey
Ages 18–75 · Women only
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Sites in Turkey
Ages 18–85 · Women only
Daiichi Sankyo · Sites in Turkey, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 6 · Phase 4 2
First in 2011; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 179 across 331 observational studies indexed under Endometrial Neoplasms.
Median enrollment 100 across the 33 interventional studies, 106 across the 13 observational. Of the 23 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 46 have an industry lead sponsor. The 10 most frequent:
Cukurova University is the lead sponsor of 261 studies on the registry; 48 are open to participants now.
Cukurova University has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Endometrial Neoplasms with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT06163963Istanbul UniversitySentinel Lymph Node in Early-Stage Endometrium Cancer | 2027-09 |
| NCT05489211AstraZenecaStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 46 studies in Endometrial Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.
Indocyanine Green (ICG) is a substance used in many areas of medicine, particularly in surgical procedures for vascular imaging, organ function assessment, and the treatment of various types of cancer. In recent years, this substance has also gained significant ground in gynecological cancers. The use of indocyanine green in gynecological cancers is particularly notable for its role in identifying cancer cells, performing lymph node biopsies, and performing minimally invasive surgeries.
Indocyanine green has become an important tool in the treatment of gynecological cancers, particularly in lymph node biopsies and minimally invasive surgeries. Its applications are increasingly expanding as it helps identify the path of cancer spread and enhances surgical precision. This substance allows surgeons to perform more accurate and effective interventions while also accelerating patient recovery.
Sentinel lymph node (SLN) mapping is increasingly used in gynecologic cancers as a less morbid staging method, an alternative to systematic pelvic and para-aortic lymphadenectomy. Numerous prospective studies have demonstrated the accuracy and reliability of the SLN technique, particularly in endometrial, cervical, and vulvar cancers. Indocyanine green (ICG), when used in conjunction with near-infrared fluorescence imaging, has become the most frequently used method due to its high sensitivity and bilateral detection rate.Patients diagnosed with endometrial, cervical, and vulvar cancer and scheduled for SLN mapping will be included in the study; potential confounding variables such as patient characteristics (age, BMI, comorbidities), tumor characteristics (histology, stage), surgical approach, and surgeon experience will also be considered in the analyses. Indocyanine green administration in gynecological cancers:
Standard storage conditions:
Storage at 2-8°C (refrigerated) in dark glass vials protected from light and moisture.
Short-term storage at room temperature (15-25°C) after preparation is suitable. Use within 24 hours is recommended. In this study, sentinel lymph node mapping will be performed by injecting 1 cc of indocyanine green diluted with sterile water (25 mg + 20 mL water → 1.25 mg/mL) into the submucosa of the cervical os at the 3-9 o'clock positions.
Prepared ICGs will be stored in a dark environment at +4°C.
The data obtained will evaluate the effects of the dosage on mapping success and also reveal the potential effects of indocyanine green storage conditions on efficacy and cost. This study aims to contribute to the development of a safer, more effective, and more economical mapping method for gynecological cancers.
Parameters used in this study:
Women who have endometrial or cervical or vulvar cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Sentinel lymph node detection success rate associated with optimized indocyanine green (ICG) dosage and storage conditions.
Time frame: Baseline (pre-procedure), perioperative/periprocedural period, and up to 24 weeks post-procedure.
Impact of optimizing indocyanine green (ICG) dosage and storage conditions on total procedural cost.
Time frame: Baseline (pre-procedure) and up to 24 weeks post-procedure.
Plan to share: Yes
Supporting information: Study protocol
Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 10 months after the start.
Of 130 non-industry observational studies under Endometrial Neoplasms, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 206. This study's planned 10 months is below that.
Counting every sponsor, half of 150 studies reached it within 105 months; a quarter within 32 and three quarters within 206.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.